1 min read

New Data Shows MR CLEAN Trial Results Extend to at Least Two Years

New Data Shows MR CLEAN Trial Results Extend to at Least Two Years

stent-403500-edited.png

“I think it will help you as a doctor to know you’re doing a treatment not only for 3 months, but that the treatment benefit is going to last for at least 2 years,” said Yvo Roos, MD. “It’s going to help you be more convincing to the relatives that you’re doing the right thing, that you’re doing something that’s really going to help them."

The above quote is in reference to new long-term followup data published as of April 6th, 2017, which now confirms and extends the outcomes of the MR CLEAN endovascular therapy trial in acute ischemic stroke patients.  The results show that 1 out of every 3 patients treated with catheter based intervention are returning home to care for themselves within 3 months and these results are durable up to 2 years! Read the full details of the follow up data right here

LEARN ABOUT PULSARA

Optimize Your Transfer Operations with Pulsara TRANSFER OPS

Optimize Your Transfer Operations with Pulsara TRANSFER OPS

Leverage Existing Pulsara Capabilities for Streamlined Patient Movement Efficient patient transfers are the lifeblood of a well-functioning...

Read More >>
Baker to Vegas: Leveraging Pulsara to Manage a Planned Event

Baker to Vegas: Leveraging Pulsara to Manage a Planned Event

Although they have the advantage of prior awareness and preparation, large-scale planned events pose unique challenges for emergency management...

Read More >>
Pulsara Introduces New ‘Secure-ish’ Messaging Feature

Pulsara Introduces New ‘Secure-ish’ Messaging Feature

For Those Who Love a Good "Oopsie!" At Pulsara, we pride ourselves on enabling secure, HIPAA-compliant communication for healthcare teams. But let’s...

Read More >>